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Background: Metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are involved in
several key pathways of tumor growth, invasion and metastasis, but little is known about their expression according
to different molecular subtypes of breast cancer. The aims of this study were to assess the prevalence and clinical
significance of MMP and TIMP expression in invasive breast cancer and to determine its association with
immunohistochemical-based molecular classification.
Methods: Tissue microarray sections were immunostained for estrogen receptor-α (ER-α), progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2), cytokeratin (CK) 5/6, epidermal growth factor receptor
(EGFR) and with specific antibodies against MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3. Based on the
immunostaining data from five of the markers used (ER-α, PR, HER2, EGFR and CK5/6), three major subtypes
(123 luminal A, 31 basal-like, and 17 HER2-overexpressing) were selected.
Results: Statistically significant differences in the expression of MMPs and TIMPs among the three subtypes were
found in tumoral MMP7 (P = 0.005), tumoral MMP-9 (P = 0.000), tumoral MMP-13 (P = 0.016) and stromal MMP-13
(P = 0.016). The incidence of tumoral MMP-9 expression in the HER2-overexpressing subtype was significantly higher
than in the luminal A subtype (P = 0.021). Tumoral MMP-9 and stromal MMP-13 expression were significantly higher
in the HER2-overexpressing subtype than in the basal-like subtype (P = 0.000 and P = 0.016, respectively). Tumoral
MMP-7 expression was significantly higher in the basal-like subtype compared to luminal A (P = 0.007) and HER2-
overexpressing subtype (P = 0.004). Tumoral MMP-13 showed a higher expression in the basal-like subtype than in
the HER2-overexpressing subtype (P = 0.010). In multivariate analysis, stage and stromal MMP-1 expression were
significantly related to overall survival. Stage was of independent prognostic significance for disease-free survival.
Conclusion: We found some variations in MMP and TIMP expression among the immunohistochemical-based
molecular subtypes of breast carcinomas, suggesting differences in their tumor pathophysiology. Additional
studies are needed to determine the mechanisms underlying the differences of MMP and TIMP expression in the
molecular subtypes for the development of specific therapeutic targets for breast cancer subtypes.
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Breast cancer is the second most common malignancy in
Korean women representing 16% of all female cancers [1].
Breast carcinoma encompasses a group of very heteroge-
neous diseases including a number of distinct entities with
specific pathological features and biological behavior [2,3].
Microarray profiling of breast carcinoma has identified
five distinct subtypes of tumors (luminal A, luminal B,
normal breast-like, human epidermal growth factor re-
ceptor 2 (HER2)-overexpressing, and basal-like) that are
associated with different clinical outcomes [4-7]. Although
this classification system is based on extensive genetic
profiling assays, a simplified method of classification based
on immunohistochemical surrogates is appealing and
more clinically useful. Based on the immunostaining
data from five markers [estrogen receptor-α (ER-α),
progesterone receptor (PR), HER2, cytokeratin (CK) 5/6,
and epidermal growth factor receptor (EGFR)], breast car-
cinoma can be categorized as luminal A (ER-α + and/or
PR+ and HER2-); luminal B (ER-α + and/or PR+ and
HER2+); HER2-overexpressing (ER-α- and PR- and HER2+);
basal-like (ER-α-, PR-, HER2- and EGFR or CK 5/6+); and
unclassified (ER-α-, PR-, HER2-, EGFR-, and CK 5/6-) [8,9].
Compared with the luminal subtype, basal-like and HER2-
overexpressing breast cancers are associated with worse
overall and disease-free survival rates [6,7]. Basal-like carcin-
oma has a triple–negative phenotype (ER-α-, PR-, and
HER2-); as a result, the majority of these tumors cannot be
managed effectively with existing targeted treatment (includ-
ing Trastuzumab and hormonal treatments) [10]. Therefore,
there is a need for the development of new therapies specif-
ically for basal-like breast cancer.
Matrix metalloproteinases (MMPs) and their tissue in-
hibitors of metalloproteinases (TIMPs) act in concert to
control extracellular matrix turnover [11,12]. MMP and
TIMP expression is altered in both benign and malig-
nant tumors, as well as in invasion and metastasis which
require breakdown and removal of the extracellular matrix
[13,14]. The central role of MMPs and TIMPs in tumor
invasion and metastasis makes them an attractive target
for drug development [15].
Previous studies have shown the expression and activ-
ity of MMPs to be linked to the advanced stage of breast
cancer, increased invasion of tumor cells and building of
metastatic formations [16-18]. Likewise, it has been re-
ported that TIMPs may be overexpressed and/or related
to clinical outcome of breast carcinoma [16]. However,
the association between MMP and TIMP expression and
the distinct molecular subtypes of breast carcinoma has
not been well investigated [17,19].
We designed this study to analyze different expression
levels of MMPs and TIMPs in breast carcinoma with respect
to immunohistochemical-based molecular classification and
to determine their relationship to other clinical-pathologicalfactors. MMPs and TIMPs, which are known to be involved
in breast carcinogenesis (MMP-1, 2, 7, 9, 11, 13, and 14 and
TIMP-1, 2, and 3), were selected and assessed using
the immunohistochemistry of three major subtypes of
invasive breast carcinomas (luminal A, basal-like, and
HER2-overexpressing); based on the immunohistochemi-
cal findings of ER-α, PR, HER2, EGFR, and CK5/6.
Methods
Case selection
Histologic files of Chonnam National University Hospital,
Gwangju, Korea from the period between 1997 and 2002
were searched for invasive breast carcinoma. We selected
204 cases with a minimum of 10 years of follow-up.
Tumor tissue was obtained from patients with unilateral
breast carcinoma after surgical resection. We excluded
patients with distant metastases at the time of initial
diagnosis or with bilateral breast carcinoma at diagno-
sis. Furthermore, patients who had received neoadju-
vant therapy, or who had a prior history of any kind of
cancer, were excluded from this study. All samples were
obtained with informed consent under protocols approved
by the institutional review board of the Chonnam National
University Hospital. Full clinical and pathological data were
collected and known for all participants.
Tissue microarray construction
The arrays were constructed with a 1.5 mm punch on
the Beecher arrayer. The array layout in the grid format
was designed using Microsoft Excel. Hematoxylin and
eosin-stained sections were reviewed and the area of
interest was marked out on the slide. Using a marker pen,
the corresponding region was circled on the archival
‘donor’ paraffin block. The samples were then arrayed on
to a ‘recipient’ blank block. Each sample was arrayed in
triplicate to minimize tissue loss and overcome tumor
heterogeneity.
Immunohistochemistry and silver-enhanced in situ
hybridization
Tissue microarray sections were immunostained for ER-α,
PR, HER2, CK 5/6, and EGFR and specific antibodies
against MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2,
and 3. Automated immunohistochemical staining was
performed using the Bond-max system (Leica Microsystems,
Bannockburn, IL), which is a device able to process up to 30
slides at a time. Slides carrying tissue sections that were cut
from paraffin-embedded tissue microarray blocks were
labeled and dried for 1 hour at 60°C. These slides were then
covered by Bond Universal Covertiles (Leica Microsystems)
and placed into the Bond-max instrument. All subse-
quent steps were performed by the automated instru-
ment according to the manufacturer’s instructions (Leica
Microsystems), in the following order: (1) deparaffinization
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Microsystems) at 72°C for 30 minutes; (2) heat-induced
epitope retrieval (antigen unmarking) with Bond Epitope
Retrival Solution 1 (Leica Microsystems) for 20 minutes
at 100°C; (3) peroxide block placement on the slides
for 5 minutes at ambient temperature; and (4) incubation
with ER-α (1:35, clone 1D5, DakoCytomation, Glostrup,
Denmark), PR (1:50, clone PgR 636, DakoCytomation),
HER2 (1:250, DakoCytomation), CK5/6 (1:50, clone D5/6
B4, DakoCytomation), EGFR (1:200, clone H11, DakoCy-
tomation), MMP-1 (1:50, Thermo Fisher Scientific, Fremont,
CA), MMP-2 (1:25, clone A-Gel VC2, Thermo Fisher
Scientific), MMP-7 (1:200, clone ID2, Thermo Fisher
Scientific), MMP-9 (1:50, Thermo Fisher Scientific),
MMP-11 (1:100, clone SL3.05, Thermo Fisher Scien-
tific), MMP-13 (1:25, clone VIIIA2, Thermo Fisher
Scientific), MMP-14 (1:50, Thermo Fisher Scientific),
TIMP-1 (1:25, clone 102D1, Thermo Fisher Scientific),
TIMP-2 (1:200, clone 3A4, Thermo Fisher Scientific), and
TIMP-3 (1:50, clone Z188, Santa Cruz Biotechnology,
Santa Cruz, CA) primary antibodies for 15 minutes at
ambient temperature; (5) incubation with Post Primary
Regent (Leica Microsystems) for 8 minutes at ambient
temperature, followed by washing with Bond Wash Solu-
tion (Leica Microsystems) for 6 minutes; (6) Bond Polymer
(Leica Microsystems) placement on the slides for 8 minutes
at ambient temperature, followed by washing with Bond
Wash and distilled water for 4 minutes; (7) color develop-
ment with DAB (3,3’-diaminobenzidine tetrahydrochloride)
as chromogen for 10 minutes at ambient temperature; and
(8) hematoxilyn counterstaining for 5 minutes at ambient
temperature, followed by mounting of the slides. Paraffin
sections of normal breast were used as positive controls for
CK5/6, sections of breast carcinoma were used for ER-α,
PR, HER2, MMPs, and TIMPs positive controls, and a
squamous cell carcinoma of the skin was used for EGFR’s
positive control. The primary antibody incubation step
was omitted in the negative control.
Tissue microarrays were digitized (Aperio Technologies,
Vista, CA) and semi-quantified estimation for immunore-
activity was performed in all cases. Tumor cells that
showed nuclear staining for ER-α or PR were considered
ER-α + or PR+, whereas all ER- or PR- cases showed a
complete absence of tumor cell staining. Of note, low
positive ER or PR (1-10% of tumor cell nuclei staining)
and positive ER or PR (>10% of tumor cell nuclei staining)
were collapsed into a single ER or PR ‘positive’ category
for the purposes of this analysis. Results of HER2 immu-
nostaining were scored according to the ASCO/CAP
guidelines. HER2 immunostaining was considered positive
when strong (3+) membranous staining was observed
in at least 30% of tumor cells, whereas cases with 0 to
1+ were regarded as negative. Cases with equivocal (2+)
result for HER2 immunostaining were retested bysilver-enhanced in situ hybridization (SISH). HER2
SISH testing and scoring were performed as described
previously below [20]. Briefly, INFORM® HER2 DNA and
Chromosome 17 probes (Ventana Medical System) were
done on the microarray sections using the Benchmark®
automatic immunostaining device in accordance with the
Ventana’s protocol. HER2 signals were scored according
to the 2008 ASCO/CAP guidelines. Any degree of cyto-
plasmic immunostaining for CK 5/6 and any degree of
distinct membranous staining for EGFR were considered
as positive expression. A case was classified as positive if
there was positive staining in any of the three cores from
that case and negative if there was no immunostaining.
MMP and TIMP immunoreactivity in the tumor tissue
and in the surrounding stromal tissue was evaluated. We
could differentiate tumor cells from stromal cells based
on their distinctive morphologies. Tumor cells are larger
than stromal cells. In addition, tumor cells show nucleoli
and are arranged in tubules, irregular nests, or solid
sheets. Stromal cells are fibroblasts or mononuclear in-
flammatory cells. A scoring system was used to describe
both the intensity of staining (negative, weak, moderate,
and strong) and the proportion of positive cells (0%, 1-25%,
26-50%, 51-75%, and 76-100%) in each case. To enable the
analysis of the individual immunostaining results, integer
values were assigned to the intensity score (0–3) and to the
proportion of stained cells (0–4). The percentages of MMP
and TIMP immunoreactive cells were evaluated from two
separate protein stained fields per core under 400x magnifi-
cation. These values were added together to provide a sin-
gle integrated score for each MMP or TIMP, and the
average data of three cores were used for further analysis.
Tumors having a final staining score of >2 were considered
positive [5].
Immunohistochemical-based molecular classification
Cancers were categorized as luminal A (ER-α + and/or
PR+ and HER2-); luminal B (ER-α + and/or PR+ and
HER2+); HER2-overexpressing (ER-α-, PR-, and HER2+);
basal-like (ER-α-, PR-, HER2- and EGFR+ or CK5/6); and
unclassified (ER-α-, PR-, HER2-, EGFR-, and CK 5/6-).
Statistical analysis
Tumor characteristics and expression of MMPs and TIMPs
were compared across different breast cancer subtypes
using the exact χ2 test for categorical data and the nonpara-
metric Kruskal-Wallis test for continuous data. Survival
curves were estimated using the Kaplan-Meier method.
The distribution of survival was compared using the log-
rank test. Multivariate analysis was performed using the
Cox’s proportional hazard model. In the multivariate ana-
lysis, we included only parameters that achieved statistical
significance for relapse-free survival or overall survival in
the log-rank test.
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Out of the 204 patients with invasive breast carcinoma
we surveyd, 123 (60.3%) were luminal A; 17 (8.3%), luminal
B; 31 (15.2%), basal-like; 17 (8.3%), HER2-overexpreessing;
and 16 (7.8%), unclassified (Figure 1). For the present
study, we selected the three most frequent types: luminal
A, basal-like, and HER2-overexpressing subtypes. Table 1
shows the clinicopathologic characteristics of the study
subjects across the three subtypes of breast cancer.
Our results did not show significant differences be-
tween the three types with regard to age, tumor size,
nodal status, and stage. However, significant differences
among the three subtypes of breast carcinoma were found
for histologic grade (P = 0.000). Both the basal-like and
HER2-overexpressing subtypes were associated with a
higher grade than the luminal A group (P = 0.000 and
P = 0.000, respectively).
Expression of MMPs and TIMPs
Immunostaining data was available for all markers in
the basal-like and HER2-overexpressing subtypes. In
the luminal A subtype, immunostaining data was avail-
able for all markers in 123 cases except for TIMP1.
TIMP1 was available for interpretation in 122 of the
123 cases. Figure 2 shows the examples of tissueFigure 1 Representative cases of luminal A (L), HER2-overexpressing
receptor-α (ER- α), progesterone receptor (PR), human epidermal gro
growth factor receptor (EGFR).microarrays with immunostaining for MMPs and TIMPs.
Immunostaining for each protein was localized to neo-
plastic cells but also visible in stromal cells around the
tumor. Tumor cells showed a greater expression of MMPs
and TIMPs than stromal cells except for MMP-1.
Tumoral MMP-7 (P= 0.005), tumoral MMP-9 (P= 0.000),
tumoral MMP-13 (P = 0.016) and stromal MMP-13
(P = 0.016) expression showed statistically significant differ-
ences among the three subtypes (Table 2). The incidence
of tumoral MMP-9 expression in the HER2-overexpressing
subtype was significantly higher than in the luminal A sub-
type (P = 0.021) and the basal-like subtype (P = 0.000).
Stromal MMP-13 expression was significantly higher in
the HER2-overexpressing subtype than in the basal-like
subtype (P = 0.016).
Tumoral MMP-7 expression was significantly higher
in the basal-like subtype compared to the luminal A
subtype (P = 0.007) and the HER2-overexpressing sub-
type (P = 0.004). Tumoral MMP-13 expression showed a
higher expression in the basal-like subtype than in the
HER2-overexpressing subtype (P = 0.010).
Correlation with patient survival
Survival data of the three subtypes was available for all 171
patients (mean follow-up 117.3 months, median, 131 months;
range, 1–190 months). Fourty-seven patients experienced
local recurrence or metastasis (11 with local recurrence
and 36 with distant metastases), and 124 remained disease
free. There were 50 deaths due to breast carcinoma.
In univariate long-rank analysis, tumor size (P = 0.000),
status of nodal involvement (P = 0.000), tumor stage(H), basal-like (B) subtype with immunostaining of estrogen
wth factor receptor 2 (HER2), cytokeratin (CK) 5/6, and epidermal









Mean ± SD 46.0 ± 10.5 48.2 ± 10.8 47.5 ± 10.2
Median (range) 45 (21–89) 46 (30–70) 45 (30–70)
Grade 0.000
1 25 (20.3%) 0 (0) 0 (0)
2 72 (58.5%) 3 (9.7%) 8 (47.1%)
3 26 (21.1%) 28 (90.3%) 9 (52.9%)
Tumor size (cm) 0.113
2≤ 34 (27.6%) 6 (19.4%) 5 (29.4%)
2-5 77 (62.6%) 17 (54.8%) 8 (47.1%)




0 63 (51.2%) 16 (51.6%) 9 (52.9%)
1-3 32 (26.0%) 9 (29.0%) 4 (23.5%)
4-9 17 (13.8%) 3 (9.7%) 3 (17.6%)
10 11 (8.9%) 3 (9.7%) 1 (5.9%)
Stage 0.981
I 27 (22.0%) 6 (19.4%) 4 (23.5%)
II 65 (52.8%) 17 (54.8%) 8 (47.1%)
III 31 (25.2%) 8 (25.8%) 5 (29.4%)
* P value obtained using the nonparametric Kruskal-Wallis test for continuous
data and the exact chi-square test for categorical data.
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were significantly associated with overall survival (Figure 3).
Tumor size (P = 0.000), status of nodal involvement
(P = 0.000), tumor stage (P = 0.000), and tumoral TIMP-3
expression (P = 0.026) were significantly associated withFigure 2 Examples of tissue microarrays with immunostaining for m
metalloproteinases (TIMPs).disease-free survival (Figure 4). All statistically significant
variables from the univariate analyses were entered into
multivariate Cox regression analysis (Table 3). Multivari-
ate analysis subsequently showed that stage and stromal
MMP-1 expression were significantly related to overall
survival. Stage was of independent prognostic significance
for disease-free survival.
Discussion
Microarray profiling of invasive breast carcinomas has
identified several distinct molecular subtypes of tumors
[4-7]. In accordance with this view, we propose that mo-
lecular subtypes are likely to contain distinct MMP/
TIMP patterns. In this study, we analyzed the differences
in the immunoreactivity of MMPs (MMP-1, 2, 7, 9, 11,
13, and 14) and TIMPs (TIMP-1, 2, and 3) in breast
carcinoma representing three subtypes, luminal A, HER2-
overexpressing, and basal-like, based on immunohis-
tochemical findings. We demonstrated that tumoral
MMP-7, tumoral MMP-9, tumoral MMP-13 and stromal
MMP-13 expression were statistically significantly differ-
ent among the three subtypes.
Gene expression profiling with breast carcinomas has
identified five distinct subtypes of the disease: luminal A,
luminal B, normal breast-like, HER2-overexpressing, and
basal-like [4-7]. Although these molecular subtypes cor-
relate with prognosis and response to therapy, the use of
gene expression profiling has been limited by issues such
as cost, complexity, and technical expertise. Subsequent
studies have proposed novel immunohistochemistry panels
to classify breast cancer into five distinct subtypes. These
panels use five markers (ER-α, PR, HER2, CK 5/6, and
EGFR) to categorize molecular subtypes as luminal A
(ER-α + and/or PR+ and HER2-); luminal B (ER-α + and/
or PR+ and HER2+); HER2-overexpressing (ER-α- andetalloproteinases (MMPs) and their tissue inhibitors of
Table 2 Immunohistochemical results of MMPs and TIMPs in
each subtype














Tumoral 13/123 (10.6) 3/31 (9.7) 2/17 (11.8) 1.000
Stromal 96/123 (78.0) 22/31 (71.0) 13/17 (76.5) 0.470
MMP 2
Tumoral 47/123 (38.2) 11/31 (35.5) 7/17 (41.2) 0.935
Stromal 4/123 (3.3) 2/31 (6.5) 0/17 (0) 0.641
MMP 7
Tumoral 100/123 (81.3) 31/31 (100) 12/17 (70.6) 0.005
Stromal 35/123 (28.5) 11/31 (35.5) 5/17 (29.4) 0.767
MMP 9
Tumoral 28/123 (22.7) 11/31 (35.5) 12/17 (70.6) 0.000
Stromal 6/123 (4.9) 0/31 (0) 0/17 (0) 0.507
MMP 11
Tumoral 115/123 (93.5) 30/31 (96.8) 17/17 (100) 1.000
Stromal 101/123 (82.1) 29/31 (93.5) 13/17 (76.5) 0.253
MMP 13
Tumoral 45/123 (36.6) 17/31 (54.8) 12/17 (70.6) 0.016
Stromal 9/123 (7.32) 5/31 (16.1) 5/17 (29.4) 0.016
MMP 14
Tumoral 67/123 (54.5) 21/31 (67.7) 12/17 (70.6) 0.331
Stromal 42/123 (34.1) 5/31 (16.1) 5/17 (29.4) 0.118
TIMP 1
Tumoral 64/122 (52.5) 12/31 (38.7) 10/17 (58.8) 0.274
Stromal 22/122 (18.0) 4/31 (12.9) 2/17 (11.8) 0.748
TIMP 2
Tumoral 62/123 (50.4) 16/31 (51.6) 11/17 (64.7) 0.657
Stromal 16/123 (13.0) 6/31 (19.4) 4/17 (23.5) 0.368
TIMP 3
Tumoral 100/123 (81.3) 27/31 (87.1) 16/17 (94.1) 0.605
Stromal 45/123 (36.6) 18/31 (58.1) 8/17 (47.1) 0.107
* P value obtained using the exact chi-square test.
Figure 3 Kaplan-Meier overall survival curves for stromal
MMP-1 expression.
Figure 4 Kaplan-Meier disease-free survival curves according to
tumoral TIMP-3 expression.
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or CK 5/6+); and unclassified (ER-α-, PR-, HER2-, EGFR-,
and CK 5/6-) [8,9].
Several studies have shown that the basal-like and HER2-
overexpressing subtypes have a higher histologic grade than
the luminal subtype. In addition, the luminal subtype was
shown to have better prognosis than the basal-like and
HER2-overexpressing subtypes [21,22]. Likewise, the present
study found that the basal-like and HER2-overexpressing
subtypes showed a higher histologic grade than the luminalA subtype. However, our study showed no statistically sig-
nificant difference among the immunohistochemical-based
molecular subtypes for overall and disease-free survival.
Therapy targeting the ER or HER2 oncogene is effect-
ive for the luminal and HER2-overexpressing subtypes.
However, the basal-like subtype is resistant to targeted
therapies such as hormonal therapy or trastuzumab
therapy [10]. Hence, studies to identify specific targeted
therapies for the basal-like subtype of breast carcinoma
Table 3 Multivariate analysis with Cox’s proportional hazards model for prognostic factors in breast cancer patients
Overall survival Disease-free survival
HR 95% CI P-value* HR 95% CI P-value*
Tumor size (≤2 or >2 cm) 2.873 0.85-9.73 0.090 3.153 0.93-10.71 0.066
Lymph node status (negative or positive) 1.088 0.45-2.62 0.851 1.988 0.83-4.75 0.122
Stage (I, II or III) 4.454 2.46-8.06 0.000 3.577 1.926-6.643 0.000
Stromal MMP-1 expression (negative or positive) 0.528 0.29-0.98 0.042 - - -
Tumor TIMP-3 expression (negative or positive) - - - 3.003 0.71-12.63 0.133
* Multivariate analysis was carried out on all variables that were found to be significant in univariate analysis.
HR, hazard rate; CI, confidence interval; −, not significant in univariate analysis.
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stem cell marker Bmi-1, lysyl oxidase-like 2 (LOXL2),
FOXC1, α9β1 integrin, and monocarboxylate transporter
1 were studied to find specific markers for basal-like
breast carcinoma [23-27]. Lee et al. [28] found that the
basal-like type of breast carcinoma displays a distinct pro-
motor methylation pattern. Thus, we wanted to analyze
the expression of MMPs and TIMPs in the three
immunohistochemical-based subtypes of breast carcin-
oma to discover a potential therapeutic target of the
basal-like subtype of breast carcinoma.
MMPs and TIMPs play a role in cancer progression
including tumor growth, invasion and metastasis [13,14].
Numerous investigators have reported the significance
of MMPs and TIMPs in breast carcinoma. Currently,
28 MMPs and 4 TIMPs are known to exist. Among
these, MMP-1, 2, 9, 11, TIMP-1, 2 levels have been
largely investigated in breast carcinoma tissues.
A few studies have previously investigated the expres-
sion of MMPs and TIMPs in various molecular subtypes
of breast carcinoma. McGowan and Duffy [17] investi-
gated the mRNA expression of MMPs in breast cancer
by analysis of a published database. Using univariate
analysis, they reported that, among 17 different MMPs,
MMP-1, 9, 12, 14 and 15 were associated with poor out-
come. Of the 5 MMPs, only MMP-14 was determined to
be an independent predictor of patient outcome. They
also investigated the differences of MMP expression be-
tween the basal subgroup and other subgroups (normal-
type, luminal A, luminal B and HER-2). They found
that mRNA expression of MMP-1, 7, 9, 12 and 15 was
significantly elevated in the basal type compared with
all the other subtypes combined. González et al. [19]
performed an immunohistochemical study of MMP-1,
2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3 on cancer
specimens from 93 patients with luminal A (n = 48) or
basal-like (n = 45) lesions. There were no significant dif-
ferences in the expression of MMPs or TIMPs in the two
phenotypes of tumors.
In the present study, we studied the expression MMPs
and TIMPs in the luminal A and basal-like subtypes aswell as in the HER2-overexpressing subtype, using a
greater number of cases than the previous study by
González et al. [19]. Because the crosstalk between
cancer- and the surrounding stromal-cells is essential
to fine tune the invasivity of cancer cells, we analyzed
the differences in the immunoreactivity of MMPs
(MMP-1, 2, 7, 9, 11, 13, and 14) and TIMPs (TIMP-1, 2,
and 3) in the tumor tissue and in the surrounding stromal
tissue of the three major immunohistochemical-based
molecular subtypes of breast carcinoma.
Our results demonstrated some significant differences
in the tumoral and stromal expression of MMPs and
TIMPs depending on the immunohistochemical-based
molecular subtype. The expression of tumoral MMP-9
was significantly elevated in the HER2-overexpressing sub-
type compared with the luminal A subtype and the basal-
like subtype. The incidence of stromal MMP-13 expression
was significantly higher in the HER2-overexpressing sub-
type than in the basal-like subtype. In agreement with our
results, several studies have also shown that MMP-9 and
MMP-13 are correlated with HER overexpression. MMP-9
(gelatinase B) is known to play a role in the invasion
and metastasis of cancer through degradation of type
IV collagen in the basement membrane and by indu-
cing angiogenesis [29,30]. High MMP-9 expression was
associated with HER2 overexpression [31-33]. MMP-13
(collagenase-3) expression in breast carcinomas was first
reported by Freije et al. [34]. MMP-13 may play a key role
in the MMP activation cascade [35]. Several studies sug-
gested that MMP-13 might play a critical role in bone me-
tabolism and even induce bone metastasis of breast
cancer by activating MMP-9 and other enzymes [36-40].
Zhang et al. [41,42] reported that tumoral MMP-13 is cor-
related with HER2 expression.
Matrix metalloproteinase −7 degrades type IV colla-
gen, fibronectin and laminin [16]. Dey et al. [43] found
that MMP-7 mRNA level was high in the triple negative
breast cancer and this result was associated to the loss
of PTEN. Our study showed that tumoral MMP-7 ex-
pression was significantly higher in the basal-like sub-
type compared the luminal A subtype as well as the
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cidence of tumoral MMP-13 expression was significantly
higher in the basal-like subtype than in the HER2-
overexpressing subtype.
TIMP-3 may be an important component in inhibiting
angiogenesis and stimulating apoptosis [13]. Mylona et al.
[44] reported that reduced expression of tumoral TIMP-3
protein was correlated with an aggressive tumor pheno-
type and shortened disease-free survival in lymph-node-
positive patients. Likewise, Span et al. [45] found that high
tumor levels of TIMP-3 was associated with longer
relapse-free survival in breast cancer patients treated
with tamoxifen. Conversely, Vizoso et al. [16] reported
that TIMP-3 expression by stromal cells correlated
positively with the occurrence of distant metastases.
Similarly, del Casar et al. [46] demonstrated that stro-
mal TIMP-3 expression was elevated in primary tu-
mors of patients with distant metastasis, although the
result was not statistically significant. Jiang et al. [47]
also found that TIMP-3 expression was higher in breast
cancer with lymph node metastasis than in those without
metastasis. However, the explanation for this discrepancy
remains unknown. One possible explanation for these dif-
ferences can be attributed to the different methods used
for the assessment of TIMP3 expression. The present
study demonstrated that, in a univariate analysis, TIMP-3
expression was significantly associated with shortened
disease-free survival in patients with breast carcinoma.
However, in a multivariate analysis, tumoral TIMP-3 ex-
pression was not determined as an independent prognos-
tic factor for poor disease-free survival (P = 0.133).
Vizoso et al. [16] found that high expression of
MMP-1 by fibroblasts was associated to the metastases.
Przybylowska [48] et al. described that MMP-1 correlated
with the local invasion. Conversely, in the present study,
stromal MMP-1 expression was determined as an inde-
pendent prognostic factor for good overall survival.
In the present study, tumoral MMP-7 and tumoral
MMP-13 expression was higher in the basal-like subtype
than the luminal A subtype or the HER2-overexpressing
subtype. However, we could not find the prognostic sig-
nificance of MMP-7 and MMP-13 in the basal-like sub-
type. A caveat with our study is that the specificities of
commercial antibodies used were not proven using in
situ hybridization, which may contribute to differences
between studies. Our study is also limited by the small
number of cases of the basal-like subtype. Therefore,
more studies using a much larger sample size, especially
those with the basal-like breast carcinoma, are needed to
define the potential prognostic role of MMPs and TIMPs
in breast carcinoma. Also, additional studies are needed to
determine the mechanisms underlying the differences of
MMPs expression in the molecular phenotypes of breast
cancer.Conclusion
Our research demonstrated some significant differ-
ences between MMP and TIMP expression in three
immumohistochemical-based molecular subtypes. Tu-
moral MMP-7 and tumoral MMP-13 expression were
significantly higher in the basal-like subtype compared to
the luminal A subtype or the HER2-overexpressing sub-
type. Further studies are required to identify the distinct
role of MMPs and TIMPs in the basal-like breast
carcinoma.
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